FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063565360> ?p ?o ?g. }

• W2063565360 endingPage "e106571" @default.
• W2063565360 startingPage "e106571" @default.
• W2063565360 abstract "Despite the fact that new treatment regimes have improved overall survival of patients challenged by colorectal cancer (CRC), prognosis in the metastatic situation is still restricted. The Bcl-2 family of proteins has been identified as promising anti cancer drug target. Even though small molecules targeting Bcl-2 proteins are in clinical trials, little is known regarding their effects on CRC. The aim of this study was to preclinically investigate the value of ABT-737 and Obatoclax as anticancer drugs for CRC treatment. The effects of the BH3-mimetics ABT-737 and Obatoclax on CRC cells were assessed using viability and apoptosis assays. Wound healing migration and boyden chamber invasion assays were applied. 3-dimensional cell cultures were used for long term assessment of invasion and proliferation. Clinically relevant concentrations of pan-Bcl-2 inhibitor Obatoclax did not induce cell death. In contrast, the BH3-mimetic ABT-737 induced apoptosis in a dose dependent manner. Obatoclax caused a cell line specific slowdown of CRC cell growth. Furthermore, Obatoclax, but not ABT-737, recovered E-Cadherin expression and led to impaired migration and invasion of CRC cells. The proliferative capacity and invasiveness of CRC cells was strikingly inhibited by low dose Obatoclax in long term 3-dimensional cell cultures. Obatoclax, but not ABT-737, caused a G1-phase arrest accompanied by a downregulation of Cyclin D1 and upregulation of p27 and p21. Overexpression of Mcl-1, Bcl-xL or Bcl-2 reversed the inhibitory effect of Obatoclax on migration but failed to restore the proliferative capacity of Obatoclax-treated CRC cells. The data presented indicate broad and multifaceted antitumor effects of the pan-Bcl-2 inhibitor Obatoclax on CRC cells. In contrast to ABT-737, Obatoclax inhibited migration, invasion and proliferation in sublethal doses. In summary, this study recommends pan-Bcl-2 inhibition as a promising approach for clinical trials in CRC." @default.
• W2063565360 created "2016-06-24" @default.
• W2063565360 creator A5001423869 @default.
• W2063565360 creator A5025974644 @default.
• W2063565360 creator A5034991880 @default.
• W2063565360 creator A5035210789 @default.
• W2063565360 creator A5052750093 @default.
• W2063565360 creator A5066404718 @default.
• W2063565360 creator A5074782998 @default.
• W2063565360 creator A5080906069 @default.
• W2063565360 creator A5086286973 @default.
• W2063565360 date "2014-09-05" @default.
• W2063565360 modified "2023-10-14" @default.
• W2063565360 title "Pan-Bcl-2 Inhibitor Obatoclax Delays Cell Cycle Progression and Blocks Migration of Colorectal Cancer Cells" @default.
• W2063565360 cites W1604204176 @default.
• W2063565360 cites W1965119671 @default.
• W2063565360 cites W1967479801 @default.
• W2063565360 cites W1972896367 @default.
• W2063565360 cites W1979129905 @default.
• W2063565360 cites W1981989535 @default.
• W2063565360 cites W1982590355 @default.
• W2063565360 cites W1987182518 @default.
• W2063565360 cites W1992054843 @default.
• W2063565360 cites W1992947847 @default.
• W2063565360 cites W1997162663 @default.
• W2063565360 cites W2001752971 @default.
• W2063565360 cites W2002433385 @default.
• W2063565360 cites W2007772937 @default.
• W2063565360 cites W2013113192 @default.
• W2063565360 cites W2018902131 @default.
• W2063565360 cites W2021505095 @default.
• W2063565360 cites W2021520050 @default.
• W2063565360 cites W2024184486 @default.
• W2063565360 cites W2025819729 @default.
• W2063565360 cites W2026208222 @default.
• W2063565360 cites W2031641885 @default.
• W2063565360 cites W2049544802 @default.
• W2063565360 cites W2066798929 @default.
• W2063565360 cites W2071535939 @default.
• W2063565360 cites W2073482997 @default.
• W2063565360 cites W2074073812 @default.
• W2063565360 cites W2075133765 @default.
• W2063565360 cites W2076417705 @default.
• W2063565360 cites W2080667388 @default.
• W2063565360 cites W2085698468 @default.
• W2063565360 cites W2089994434 @default.
• W2063565360 cites W2094708689 @default.
• W2063565360 cites W2095554214 @default.
• W2063565360 cites W2100592123 @default.
• W2063565360 cites W2101121084 @default.
• W2063565360 cites W2104759776 @default.
• W2063565360 cites W2105420307 @default.
• W2063565360 cites W2121619780 @default.
• W2063565360 cites W2123437999 @default.
• W2063565360 cites W2128447926 @default.
• W2063565360 cites W2139503978 @default.
• W2063565360 cites W2146624383 @default.
• W2063565360 cites W2146654096 @default.
• W2063565360 cites W2153571329 @default.
• W2063565360 cites W2162774171 @default.
• W2063565360 cites W4211224216 @default.
• W2063565360 doi "https://doi.org/10.1371/journal.pone.0106571" @default.
• W2063565360 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4156353" @default.
• W2063565360 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25192188" @default.
• W2063565360 hasPublicationYear "2014" @default.
• W2063565360 type Work @default.
• W2063565360 sameAs 2063565360 @default.
• W2063565360 citedByCount "27" @default.
• W2063565360 countsByYear W20635653602015 @default.
• W2063565360 countsByYear W20635653602016 @default.
• W2063565360 countsByYear W20635653602017 @default.
• W2063565360 countsByYear W20635653602018 @default.
• W2063565360 countsByYear W20635653602019 @default.
• W2063565360 countsByYear W20635653602020 @default.
• W2063565360 countsByYear W20635653602021 @default.
• W2063565360 countsByYear W20635653602022 @default.
• W2063565360 crossrefType "journal-article" @default.
• W2063565360 hasAuthorship W2063565360A5001423869 @default.
• W2063565360 hasAuthorship W2063565360A5025974644 @default.
• W2063565360 hasAuthorship W2063565360A5034991880 @default.
• W2063565360 hasAuthorship W2063565360A5035210789 @default.
• W2063565360 hasAuthorship W2063565360A5052750093 @default.
• W2063565360 hasAuthorship W2063565360A5066404718 @default.
• W2063565360 hasAuthorship W2063565360A5074782998 @default.
• W2063565360 hasAuthorship W2063565360A5080906069 @default.
• W2063565360 hasAuthorship W2063565360A5086286973 @default.
• W2063565360 hasBestOaLocation W20635653601 @default.
• W2063565360 hasConcept C104317684 @default.
• W2063565360 hasConcept C105696609 @default.
• W2063565360 hasConcept C121608353 @default.
• W2063565360 hasConcept C126322002 @default.
• W2063565360 hasConcept C127561419 @default.
• W2063565360 hasConcept C137738243 @default.
• W2063565360 hasConcept C190283241 @default.
• W2063565360 hasConcept C199835354 @default.
• W2063565360 hasConcept C29537977 @default.
• W2063565360 hasConcept C502942594 @default.
• W2063565360 hasConcept C526805850 @default.

• next